Xtant Medical Holdings, Inc.

As of June 30, 2026, Xtant Medical Holdings, Inc. carries a market capitalization of 52.74M, placing it among publicly traded companies globally. Its enterprise value stands at 66.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Xtant Medical Holdings, Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Xtant Medical Holdings, Inc. has 140.26M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.55, and the price-to-book ratio stands at 1.51.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.70 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 66.87M versus a market cap of 52.74M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Xtant Medical Holdings, Inc. maintains a current ratio of 2.16, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.01, indicating elevated leverage, while an interest coverage ratio of -2.34 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Xtant Medical Holdings, Inc. posted a negative return on equity (ROE) of -25.16, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -12.16, reflecting losses generated across the asset base. The company generates approximately 559,818.88 in revenue per employee across its workforce of 171.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.21 indicates how many times Xtant Medical Holdings, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Xtant Medical Holdings, Inc. recorded 1.66M in income tax expense. The company reported a pretax loss of -8.09M and -9.75M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Xtant Medical Holdings, Inc.'s stock has declined approximately 59.42% over the past 52 weeks. The 50-day moving average sits at 0.30, while the 200-day moving average is 0.41.

Over the twelve months ended June 30, 2026, Xtant Medical Holdings, Inc. generated 95.87M in revenue and converted that into -9.75M in net income, yielding earnings per share of -0.07. EBITDA reached -5.67M, while operating income came in at -4.81M.

As of June 30, 2026, Xtant Medical Holdings, Inc. holds 8.64M in cash and equivalents against 22.77M in total debt, resulting in a net debt position of 11.49M. Total book value stands at 35.03M, with working capital of 30.47M providing operational flexibility.

Xtant Medical Holdings, Inc. produced 498,921.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.11M in capital expenditures, free cash flow totaled -609,208.80 - equivalent to 0.00 per share.

Over the twelve months ended June 30, 2026, Xtant Medical Holdings, Inc. posted a gross margin of 59.39, reflecting its pricing power and cost economics. The operating margin of -5.02 and net profit margin of -10.17 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 19.97, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Xtant Medical Holdings, Inc. shareholders.

Xtant Medical Holdings, Inc.'s most recent stock split took place on February 14, 2018 with a 12:1 split ratio.

As of June 30, 2026, Xtant Medical Holdings, Inc. has an Altman Z-Score of -2.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.